FDA Authorizes 23andMe to Market Genetic Testing For Bloom Syndrome — techcrunch.com

The U.S. Food and Drug Administration has given 23andMe clearance to begin selling kits for the genetic testing of Bloom Syndrome. This is a rare recessive gene disorder that is characterized by shorter height and a predisposition to develop cancer. Parents of children with Bloom Syndrome don’t exhibit any symptoms of the disorder. 23andMe’s direct-to-consumer genetic test allows someone to see if they have a specific gene variant for Bloom Syndrome and helps parents know if they could potentially pass on the gene that would cause their children to have the disorder.

Read More